Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ValiRx plc ( (GB:VAL) ) has provided an announcement.
ValiRx plc has announced the posting of a circular regarding a General Meeting scheduled for 30 December 2024, following their fundraising announcement. This meeting will address the necessary resolutions for the Admission, Placing, Broker Offer, and Subscription, which are crucial for the company’s capital raise and strategic growth initiatives. The outcomes of the General Meeting and subsequent steps are expected to impact the company’s operations and market positioning significantly.
More about ValiRx plc
ValiRx plc is a life science company specializing in early-stage cancer therapeutics and women’s health. The company focuses on accelerating the translation of innovative science into impactful medicines to improve patient lives. ValiRx provides a supportive framework for the rapid development of novel drug candidates, guiding them from pre-clinical studies to clinic and investor-ready assets.
YTD Price Performance: -86.86%
Average Trading Volume: 1,183,396
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.03M
See more insights into VAL stock on TipRanks’ Stock Analysis page.
